RP & dry AMD candidate on the fast track

Article

Neurotech Pharmaceuticals has been granted Fast Track designations by the FDA for NT-501 for the treatment of visual loss in retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

Neurotech Pharmaceuticals has been granted Fast Track designations by the FDA for NT-501 for the treatment of visual loss in retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

NT-501 is an intraocular, cell-containing polymer implant that has been developed to provide continuous, long-term release of the therapeutic protein Ciliary Neurotrophic Factor (CNTF) directly into the back of the eye via the company's proprietary Encapsulated Cell Technology.

Neurotech is currently conducting two Phase II/III trials of NT-501 for the treatment of visual loss associated with RP in both its earlier and later stages. It is also carrying out a Phase II study evaluating NT-501 in 48 patients with dry AMD.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
Related Content
A green notebook with "AAO 2024 schedule" written on the top of the page. A matching green pen rests on the notebook. Image credit: ©AndErsoN – stock.adobe.com

Strabismus surgery, glaucoma's unknowable truths and other AAO keynote lecture topics

Lynda Charters
October 11th 2024
Article

The diverse list of sessions includes discussions of surgical ethics and an arts lecture about Ansel Adams

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Her Royal Highness Sophie, Duchess of Edinburgh, holds a CBeebies plush. (Image credit: BBC/Guy Levy)

Children across the UK can celebrate World Sight Day with the Duchess of Edinburgh

Hattie Hayes
October 9th 2024
Article

Her Royal Highness will share the CBeebies Bedtime Story "Specs for Rex"

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Surgeons train on bag-in-lens procedure in Kwale Eye Centre. Image courtesy Alexander S Thrane, MD, PhD, FEBOphth

The true costs of treating paediatric cataracts

By Hattie Hayes; Reviewed by by Vinita Rangroo Thrane, MD, PhD; Alexander S. Thrane, MD, PhD, FEBOphth; and Nils-Erik Boonstra, MD
October 9th 2024
Article

A retrospective analysis illuminates discrepancies between adult and paediatric cataract procedures around the globe

A paper cutout of the globe, with paper cutouts of adults and children in front of it. Image credit: ©NiK0StudeO – stock.adobe.com

World Sight Day is Thursday, 10 October

David Hutton
October 8th 2024
Article

This year, the IAPB encourages children worldwide to love their eyes

© 2024 MJH Life Sciences

All rights reserved.